Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das · 2026

Read Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years by Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224755.txt.

Description

Lusine Kostanyan and colleagues report a 2026 phase 3 trial update for mRNA-1083, an experimental combined vaccine against seasonal flu and COVID-19 in one shot. Adults aged fifty and older were randomly assigned to the combined product or to standard licensed vaccines for each disease. Earlier results covered the first month; the new report extends follow-up to six months.

Antibody responses against all matched flu strains held up through six months and matched or beat the standard vaccines. Responses against the coronavirus stayed higher in the combined-vaccine group throughout. Side effects were mostly mild to moderate, and no vaccine-related serious events or deaths occurred, supporting the single-shot approach for older adults.

Catalog record

CREATORLusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13224755

Browse the full library · About the Tower of Babel